CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-22

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot clinical trial studies how well computed tomography (CT) perfusion images work in assessing treatment response in patients with pancreatic cancer. Analyzing specific measurements on the CT perfusion images may help doctors better determine how a tumor responds to chemotherapy and/or radiation therapy and may help guide treatment for patients with pancreatic cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

NCT02361320

Pancreatic Cancer

RECRUITING NA

Role of Perfusion CT in Pancreatic Cancer

NCT01703650

Adenocarcinoma, Pancreas Neuroendocrine Carcinoma of Pancreas

UNKNOWN

Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics

NCT05669287

PDAC - Pancreatic Ductal Adenocarcinoma

UNKNOWN NA

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

NCT00767273

Pancreatic Cancer

COMPLETED NA

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

NCT03851237

Pancreatic Ductal Adenocarcinoma

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OUTLINE:

Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.

After completion of the study, patients are followed up periodically for 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Ductal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (CT perfusion sequence)

Patients undergo CT perfusion sequence during the first 40 seconds of the baseline standard of care CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6 weeks after radiation therapy, or prior to definitive surgery.

Group Type EXPERIMENTAL

Computed Tomography Perfusion Imaging

Intervention Type DIAGNOSTIC_TEST

Undergo CT perfusion sequence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computed Tomography Perfusion Imaging

Undergo CT perfusion sequence

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent form
* A diagnosis of pancreatic ductal adenocarcinoma

Exclusion Criteria

* Patients unable to provide informed consent
* Women who are pregnant or intending to become pregnant during the study
* Patients with body mass index greater than 40 kg/m\^2
* History of severe allergic-like reaction to iodinated contrast media

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No